ClinicalTrials.gg
CompletedNCT01048866Updated Sep 21, 2017Results posted

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

A Phase 3 interventional study of placebo and flurbiprofen in Pharyngitis, sponsored by Reckitt Benckiser LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-21.

Sponsored by Reckitt Benckiser LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies in Pharyngitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pharyngitis · United States.

Enrollment
20th of 35
198 · median 204
Started
2009
with 3 others
Phase 3
18 of 41
none open now
Registered
13th of 41
by date
Lead sponsor
3 of 41
Reckitt Benckiser LLC

Among the 41 studies in Pharyngitis with a site in United States, this one is the 20th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2009, is one of 18 in phase 3, and was the 13th registered.

Pharyngitis

227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.

Browse Pharyngitis studies →

Open to participants now

4 of the 41 studies in Pharyngitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Pharyngitis studies recruiting now, 5 (26%) set no upper age limit and 10 (53%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Pharyngitis with a site in United States, or all of them as a file.
02

Study summary

The purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore throat due to acute pharyngitis.

Read the detailed description

Per randomization to the treatments and under double-blind conditions, patients were instructed to suck 1 sugar-based, flavoured flurbiprofen 8.75 mg lozenge or 1 sugar-based, flavoured matching vehicle control/placebo lozenge and remained at the study center for a 2-hour observation period to assess their responses to the study medication during the initial 2-hour post-dose period. Patients were allowed a dose of rescue medication (acetaminophen 650mg), as needed, post-treatment dosing during the study.

After the initial 2 hours in the research center, patients were discharged with an outpatient diary to continue (while awake) to document hourly assessments of Sore Throat Pain Intensity Scale (STPIS), Difficulty Swallowing Scale (DSS), and Swollen Throat Scale (SwoTS) through 24 hours. They used the assigned lozenges as needed every 3-6 hours, up to 5 lozenges over 24 hours. A Follow-Up Visit was conducted for the 24-hour assessments.

Patients received additional study lozenges for use as needed (up to 5 lozenges per 24 hours) over the following 6 days, rescue medication (acetaminophen 650 mg) and a Diary to document their safety and efficacy assessments immediately before and postdose after each as-needed use of a lozenge for the remaining days in the 7-day treatment period. At the end of the 7-day trial, patients returned to the research center for final assessments, review of adverse events over the week, and discharge from the study.

03

Conditions studied

  • Pharyngitis

Keywords

  • pharyngitis
  • swollen throat
  • difficulty swallowing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has a complaint of sore throat.
  2. If the patient is a female of , she has been using effective since the last date of menses and is not breast-feeding or lactating.
  3. If the patient is a female of childbearing potential, the patient must have a negative urine pregnancy.
  4. The patient has provided written prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. The patient has a history of an upper gastrointestinal ulcer within the past 60 days, is currently experiencing upper gastrointestinal complaints, or is currently taking medication regularly (≥ three times in the previous week).
  2. The patient has a history of any hepatic disease or renal dysfunction.
  3. The patient has a history of chronic analgesic use (≥ three times per week over the prior four weeks). (Patients on low-dose aspirin therapy may be allowed in the study per investigator's clinical decision.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    flurbiprofen 8.75 mg lozenge

    Participants were instructed to suck one study (flurbiprofen 8.75 mg) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another study medication lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use study medication lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.

    Drug: flurbiprofen · Drug: acetaminophen 650mg

  • Placebo comparator
    placebo lozenge

    Participants were instructed to suck one study (placebo) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use a lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.

    Drug: placebo · Drug: acetaminophen 650mg

Interventions

  • Drugplacebo

    Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.

  • Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.

  • Rescue medication to be taken as needed. Rescue medication was not blinded.

    Also known as: Tylenol

06

What researchers measure

Primary outcomes

  1. Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)

    STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. The full range was -104412 (complete pain relief within 1 hour of dosing that lasts 24 hours) to 27588 (maximum pain within 1 hour lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.

    Time frame: baseline (pre-dose), post-dose - hourly up to 24 hours

Secondary outcomes

  1. Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline

    DSS measures difficulty swallowing (dysphagia) using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated not difficult and 100-mm indicated very difficult. Data are reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9360 (no difficulty swallowing within 1 hour of dosing that lasts 2 hours) to 2640 (maximum difficulty swallowing within 1 hour of dosing lasting 2 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.

    Time frame: Baseline (pre-dose), Hours 1 and 2 post-dose

  2. Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline

    DSS measures difficulty swallowing (dysphagia) using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated not difficult and 100-mm indicated very difficult. Data are reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -102960 (no difficulty swallowing within 1 hour of dosing that lasts 24 hours) to 29040 (maximum difficulty swallowing within 1 hour of dosing lasting 24 hours) using the baseline DSS value. Negative values indicate improvement in difficulty swallowing. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.

    Time frame: Baseline (pre-dose), hourly readings to 24 hours post-dose

  3. Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline

    SwoTS measures how swollen a participant's throat felt using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9120 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2880 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS. Negative values for the differences indicate improvement. Missing values of SwoTS with non-missing values at assessments before and after were calculated using linear interpolation.

    Time frame: Baseline (pre-dose), hourly readings to 2 hours post-dose

  4. Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline

    SwoTS measures how swollen a participant's throat felt using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -100320 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31680 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS. Negative values for differences indicate improvement.

    Time frame: Baseline (pre-dose), hourly readings to 24 hours post-dose

  5. Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)

    STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9492 (complete pain relief within one hour of dosing that lasts 2 hours) to 2508 (maximum pain within 1 hour lasting 2 hours) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.

    Time frame: baseline (pre-dose), post-dose: 1 hour, 2 hours

  6. Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe

    STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -115695 (no pain at any post-dose time (0) - average baseline) to 28505 (maximum possible pain (100) - average baseline). Participants with their last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imput

    Time frame: baseline (pre-dose), 24 hours post dose (measured each hour post dose)

  7. Sore Throat Relief As Reported by Participants 2 Hours After Initial Dose

    Participants graded the relief of his/her sore throat at 2 hours post initial dose using the Sore Throat Relief Rating Scale (STRRS), which is a 6-category relief scale. The patient was instructed to swallow and asked: "Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now." Responses were no relief, slight, mild, moderate, considerable, and complete relief.

    Time frame: 2 hours

  8. Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose

    Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: "Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.

    Time frame: 24 hours

  9. Participant Satisfaction Score 24 Hours After Initial Dose

    After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied.

    Time frame: 24 hours

  10. Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at End of Study (Day 7)

    Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of study by answering the following question: "Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.

    Time frame: Day 7 (end of study)

  11. Post 24 Hour, Multiple Dose Results: Weighted Sum of Pain Intensity Differences (SPID) Over 2 Hours for the Sore Throat Pain Intensity Scale (STPIS SPID2)

    The time weighted summed differences over 2 hours after taking a lozenge after the initial 24-hours post-baseline. STPIS is a validated 100-mm visual analog scale completed by participants that measures "pain on swallowing" (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from a measurement taken prior to taking a lozenge and at hours 1 + 2 after taking the lozenge during Days 2-7. Data for multiple doses/days were averaged to obtain the values used for calculating SPID2. The full range for SPID2 was -5843 to 6157 with negative values indicating improvement in pain intensity. Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants.

    Time frame: Days 2-7

  12. Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Difficulty Swallowing Scale (DSS2)

    The time weighted summed differences over 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline. To measure the functional effect on pharyngitis, the participant was asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale prior to dosing, and 1 hour and 2 hours post dose. The participant was instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated not difficult and 100-mm indicated very difficult. Data for multiple doses/days were averaged to obtain the values used for calculating DSS2. The full range for differences was -5626 to 6374 with negative values indicating improvement in pain intensity. Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants.

    Time frame: Days 2-7

  13. Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Swollen Throat Scale (SwoTS2)

    The time weighted summed differences over 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline. The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale prior to dosing, and 1 hour and 2 hours post dose. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. Data for multiple doses/days were averaged to obtain the values used for calculating SWoTS2. The full range for differences was -5396 to 6604 with negative values indicating improvement in pain intensity. Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants.

    Time frame: Days 2-7

  14. Post 24 Hour, Multiple Dose Results: Sore Throat Relief As Reported by Participants 2 Hours After Dosing

    Participants graded the relief of his/her sore throat at 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline using the Sore Throat Relief Rating Scale (STRRS), which is a 6-category relief scale. The patient was instructed to swallow and: "Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now." Responses following each lozenge were no relief, slight, mild, moderate, considerable, and complete relief. Results summarize responses 2 hours after taking each lozenge.

    Time frame: Days 2-7

  15. Percentage of Participants Who Took Rescue Pain Medication

    Participants were allowed a dose of rescue medication (acetaminophen 650mg), as needed, post-treatment dosing during the study.

    Time frame: Days 1-7

  16. Time to First Rescue Pain Medication

    Participants were allowed a dose of rescue medication (acetaminophen 650mg), as needed, post-treatment during the study. Time from initial dose to first rescue medication is summarized by time categories.

    Time frame: Days 1-7

  17. Change From Baseline in Body Temperature at 2 Hours Post Initial Dose

    Time frame: baseline (pre-dose), 2 hours post-dose

  18. Change From Baseline in Body Temperature at End of Study

    Time frame: baseline (pre-dose), up to Day 7

07

Results

Posted Sep 21, 2017

Participant flow

Participant flow — Overall Study
MilestoneFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Started10197
Completed9792
Not completed45
Withdrew: Adverse event10
Withdrew: Protocol violation10
Withdrew: Physician decision10
Withdrew: Withdrawal by subject02
Withdrew: Lost to follow-up02
Withdrew: Other11

Outcome measures

PrimaryTime Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)

STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. The full range was -104412 (complete pain relief within 1 hour of dosing that lasts 24 hours) to 27588 (maximum pain within 1 hour lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.

Time frame:
baseline (pre-dose), post-dose - hourly up to 24 hours
Reported as:
Mean · units on a scale
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)-522.9 ± 476.54-326.5 ± 386.83
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0021 (The a priori threshold for statistical significance is 0.05.) · Least-square means difference: -196.6 · 95% CI -321.0 to -72.2
SecondaryTime Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline

DSS measures difficulty swallowing (dysphagia) using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated not difficult and 100-mm indicated very difficult. Data are reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9360 (no difficulty swallowing within 1 hour of dosing that lasts 2 hours) to 2640 (maximum difficulty swallowing within 1 hour of dosing lasting 2 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.

Time frame:
Baseline (pre-dose), Hours 1 and 2 post-dose
Reported as:
Mean · units on a scale
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline-37.1 ± 39.60-18.1 ± 29.43
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0002 (The a priori threshold for statistical significance is 0.05.) · Least-square means difference: -19.0 · 95% CI -28.7 to -9.3Baseline DSS fitted as a covariate and centre as a fixed effect.
SecondaryTime Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline

DSS measures difficulty swallowing (dysphagia) using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated not difficult and 100-mm indicated very difficult. Data are reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -102960 (no difficulty swallowing within 1 hour of dosing that lasts 24 hours) to 29040 (maximum difficulty swallowing within 1 hour of dosing lasting 24 hours) using the baseline DSS value. Negative values indicate improvement in difficulty swallowing. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.

Time frame:
Baseline (pre-dose), hourly readings to 24 hours post-dose
Reported as:
Mean · units on a scale
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline-555.5 ± 494.04-379.4 ± 397.66
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0054 (The a priori threshold for statistical significance is 0.05.) · Least-square means difference: -179.7 · 95% CI -305.7 to -53.8
SecondaryTime Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline

SwoTS measures how swollen a participant's throat felt using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9120 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2880 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS. Negative values for the differences indicate improvement. Missing values of SwoTS with non-missing values at assessments before and after were calculated using linear interpolation.

Time frame:
Baseline (pre-dose), hourly readings to 2 hours post-dose
Reported as:
Mean · units on a scale
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline-35.5 ± 38.92-16.9 ± 29.10
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0008 (The a priori threshold for statistical significance is 0.05.) · Least-square means difference: -16.4 · 95% CI -25.9 to -7.0
SecondaryTime Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline

SwoTS measures how swollen a participant's throat felt using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -100320 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31680 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS. Negative values for differences indicate improvement.

Time frame:
Baseline (pre-dose), hourly readings to 24 hours post-dose
Reported as:
Mean · units on a scale
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline-542.4 ± 487.67-377.4 ± 419.95
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0087 · Least-square means difference: -168.4 · 95% CI -293.7 to -43.1
SecondaryTime Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)

STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9492 (complete pain relief within one hour of dosing that lasts 2 hours) to 2508 (maximum pain within 1 hour lasting 2 hours) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.

Time frame:
baseline (pre-dose), post-dose: 1 hour, 2 hours
Reported as:
Mean · units on a scale
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)-37.1 ± 37.04-17.9 ± 26.54
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = <0.0001 · Least-square means difference: -19.0 · 95% CI -28.0 to -10.0Baseline STPIS fitted as a covariate and centre as a fixed effect.
SecondaryTime Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe

STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -115695 (no pain at any post-dose time (0) - average baseline) to 28505 (maximum possible pain (100) - average baseline). Participants with their last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imput

Time frame:
baseline (pre-dose), 24 hours post dose (measured each hour post dose)
Reported as:
Mean · units on a scale
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe-476.9 ± 492.12-351.3 ± 425.98
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.1844 · Least-square means difference: -118.9 · 95% CI -295.3 to 57.5Baseline STPIS fitted as a covariate and centre as a fixed effect.
SecondarySore Throat Relief As Reported by Participants 2 Hours After Initial Dose

Participants graded the relief of his/her sore throat at 2 hours post initial dose using the Sore Throat Relief Rating Scale (STRRS), which is a 6-category relief scale. The patient was instructed to swallow and asked: "Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now." Responses were no relief, slight, mild, moderate, considerable, and complete relief.

Time frame:
2 hours
Reported as:
Number · percentage of participants
Sore Throat Relief As Reported by Participants 2 Hours After Initial Dose
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
No relief9.938.1
Slight relief28.722.7
Mild relief27.717.5
Moderate relief17.818.6
Considerable relief15.83.1
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryInvestigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose

Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: "Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.

Time frame:
24 hours
Reported as:
Number · percentage of participants
Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Poor25.025.3
Fair27.029.5
Good26.024.2
Very Good14.012.6
Excellent8.08.4
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = 0.8827
SecondaryParticipant Satisfaction Score 24 Hours After Initial Dose

After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied.

Time frame:
24 hours
Reported as:
Number · percentage of participants
Participant Satisfaction Score 24 Hours After Initial Dose
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Extremely dissatisfied4.05.2
Very dissatisfied4.09.4
Dissatisfied10.914.6
Somewhat satisfied27.732.3
Satisfied23.826.0
Very satisified24.87.3
Extremely satisfied5.05.2
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Wilcoxon (Mann-Whitney) · p = 0.0105Stratified by centre
SecondaryInvestigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at End of Study (Day 7)

Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of study by answering the following question: "Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.

Time frame:
Day 7 (end of study)
Reported as:
Number · percentage of participants
Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at End of Study (Day 7)
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Poor19.825.0
Fair22.926.1
Good24.020.7
Very Good26.022.8
Excellent7.35.4
SecondaryPost 24 Hour, Multiple Dose Results: Weighted Sum of Pain Intensity Differences (SPID) Over 2 Hours for the Sore Throat Pain Intensity Scale (STPIS SPID2)

The time weighted summed differences over 2 hours after taking a lozenge after the initial 24-hours post-baseline. STPIS is a validated 100-mm visual analog scale completed by participants that measures "pain on swallowing" (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from a measurement taken prior to taking a lozenge and at hours 1 + 2 after taking the lozenge during Days 2-7. Data for multiple doses/days were averaged to obtain the values used for calculating SPID2. The full range for SPID2 was -5843 to 6157 with negative values indicating improvement in pain intensity. Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants.

Time frame:
Days 2-7
Reported as:
Least squares mean · units on a scale
Post 24 Hour, Multiple Dose Results: Weighted Sum of Pain Intensity Differences (SPID) Over 2 Hours for the Sore Throat Pain Intensity Scale (STPIS SPID2)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Post 24 Hour, Multiple Dose Results: Weighted Sum of Pain Intensity Differences (SPID) Over 2 Hours for the Sore Throat Pain Intensity Scale (STPIS SPID2)-22.7 ± 2.56-16.8 ± 2.61
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0743 · Least-square means difference: -5.9 · 95% CI -12.4 to 0.6Repeated measures ANOVA model with participant as a random effect.
SecondaryPost 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Difficulty Swallowing Scale (DSS2)

The time weighted summed differences over 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline. To measure the functional effect on pharyngitis, the participant was asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale prior to dosing, and 1 hour and 2 hours post dose. The participant was instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated not difficult and 100-mm indicated very difficult. Data for multiple doses/days were averaged to obtain the values used for calculating DSS2. The full range for differences was -5626 to 6374 with negative values indicating improvement in pain intensity. Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants.

Time frame:
Days 2-7
Reported as:
Least squares mean · units on a scale
Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Difficulty Swallowing Scale (DSS2)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Difficulty Swallowing Scale (DSS2)-21.0 ± 2.49-15.5 ± 2.53
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0871 · Least-square means difference: -5.5 · 95% CI -11.7 to 0.8Repeated measures ANOVA model with patient as a random effect.
SecondaryPost 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Swollen Throat Scale (SwoTS2)

The time weighted summed differences over 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline. The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale prior to dosing, and 1 hour and 2 hours post dose. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. Data for multiple doses/days were averaged to obtain the values used for calculating SWoTS2. The full range for differences was -5396 to 6604 with negative values indicating improvement in pain intensity. Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants.

Time frame:
Days 2-7
Reported as:
Least squares mean · units on a scale
Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Swollen Throat Scale (SwoTS2)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Post 24 Hour, Multiple Dose Results: Weighted Sum of Differences Over 2 Hours for Swollen Throat Scale (SwoTS2)-19.5 ± 2.49-13.4 ± 2.52
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0595 · Least-square means difference: -6.0 · 95% CI -12.3 to 0.2Repeated measures ANOVA model with participant as a random effect.
SecondaryPost 24 Hour, Multiple Dose Results: Sore Throat Relief As Reported by Participants 2 Hours After Dosing

Participants graded the relief of his/her sore throat at 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline using the Sore Throat Relief Rating Scale (STRRS), which is a 6-category relief scale. The patient was instructed to swallow and: "Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now." Responses following each lozenge were no relief, slight, mild, moderate, considerable, and complete relief. Results summarize responses 2 hours after taking each lozenge.

Time frame:
Days 2-7
Reported as:
Number · percentage of doses
Post 24 Hour, Multiple Dose Results: Sore Throat Relief As Reported by Participants 2 Hours After Dosing
percentage of dosesFlurbiprofen 8.75 mg LozengePlacebo Lozenge
No relief9.723.0
Slight relief21.724.8
Mild relief25.219.0
Moderate relief16.513.7
Considerable relief18.914.7
Complete relief8.04.9
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0195 · Least-square means difference: 0.5 · 95% CI 0.1 to 0.9Repeated measures ANOVA model with participant as a random effect.
SecondaryPercentage of Participants Who Took Rescue Pain Medication

Participants were allowed a dose of rescue medication (acetaminophen 650mg), as needed, post-treatment dosing during the study.

Time frame:
Days 1-7
Reported as:
Number · percentage of participants
Percentage of Participants Who Took Rescue Pain Medication
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Yes13.925.8
No86.174.2
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Regression, Logistic · p = 0.0322Effect for centre
SecondaryTime to First Rescue Pain Medication

Participants were allowed a dose of rescue medication (acetaminophen 650mg), as needed, post-treatment during the study. Time from initial dose to first rescue medication is summarized by time categories.

Time frame:
Days 1-7
Reported as:
Number · percentage of participants
Time to First Rescue Pain Medication
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
2 - <4 hours2.06.2
4 - <6 hours2.02.1
6 - <24 hours5.913.4
24 - <72 hours3.03.1
72 - 168 hours1.01.0
Did not rescue86.174.2
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · Log Rank · p = 0.0276
SecondaryChange From Baseline in Body Temperature at 2 Hours Post Initial Dose
Time frame:
baseline (pre-dose), 2 hours post-dose
Reported as:
Mean · degrees Fahrenheit
Change From Baseline in Body Temperature at 2 Hours Post Initial Dose
degrees FahrenheitFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Change From Baseline in Body Temperature at 2 Hours Post Initial Dose-0.2 ± 0.63-0.0 ± 0.82
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.0288 · Least-square means difference: -0.2 · 95% CI -0.4 to -0.0
SecondaryChange From Baseline in Body Temperature at End of Study
Time frame:
baseline (pre-dose), up to Day 7
Reported as:
Mean · degrees Fahrenheit
Change From Baseline in Body Temperature at End of Study
degrees FahrenheitFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Change From Baseline in Body Temperature at End of Study-0.4 ± 0.91-0.3 ± 0.94
Statistical analysis
  • Flurbiprofen 8.75 mg Lozenge vs Placebo Lozenge · ANOVA · p = 0.4274 · Least-square means difference: -0.1 · 95% CI -0.3 to 0.1

Adverse events

Collected over Initial dose on Day 1 up to Day 7. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Flurbiprofen 8.75 mg Lozenge—0/101 (0%)34/101 (33.7%)
Placebo Lozenge—0/97 (0%)28/97 (28.9%)
Most frequent other events
Showing 10 of 45
Most frequent other events
EventFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Throat irritationRespiratory, thoracic and mediastinal disorders10/1010/97
HeadacheNervous system disorders8/1016/97
ParaesthesiaNervous system disorders4/1010/97
CoughRespiratory, thoracic and mediastinal disorders4/1012/97
Pharyngitis streptococcalInfections and infestations1/1013/97
Sinus congestionRespiratory, thoracic and mediastinal disorders0/1013/97
PyrexiaGeneral disorders2/1012/97
Foot fractureInjury, poisoning and procedural complications0/1012/97
MigraineNervous system disorders0/1012/97
DiarrhoeaGastrointestinal disorders2/1011/97

Baseline characteristics

Age, Continuous
Age, Continuous(years)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean33.5 ± 11.0334.2 ± 11.1733.9 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Female6158119
Male403979
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Asian101020
Black or African131427
White6767134
Multi-racial (no primary)336
Other, not specified8311
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Hispanic or Latino161026
Non-Hispanic or non-Latino8587172
Sore Throat Pain Intensity Scale (STPIS)
Sore Throat Pain Intensity Scale (STPIS)(units on a scale)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean79.1 ± 8.0979.1 ± 8.3779.1 ± 8.21
Difficulty Swallowing Scale (DSS)
Difficulty Swallowing Scale (DSS)(units on a scale)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean77.9 ± 10.5578.2 ± 10.378.0 ± 10.45
Swollen Throat Scale (SwoTS)
Swollen Throat Scale (SwoTS)(units on a scale)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean76.0 ± 12.9076.0 ± 12.776.0 ± 12.80
08

Study locations

1 site
  • Bluestone Center for Clinical Research
    New York, New York 10010, United States
09

References and documents

Publications

  • Schachtel B, Aspley S, Berry P, Muir N, Shephard A, Shea T, Smith G, Schachtel E. Efficacy of a novel (lozenge) delivery of flurbiprofen over 24 hours. Journal of Pain 2012;13(4)Supplement:S74.
  • Aspley S, Schachtel B, Berry P, Shephard A, Shea T, Smith G, Lorton M, Schachtel E. Efficacy and safety of multiple uses of flurbiprofen 8.75mg lozenge over 1 week. Abstract presented at the 14th World Congress on Pain, 27 - 31 August 2012, Milan.
  • Shephard A, Smith G, Aspley S, Schachtel B. Efficacy of flurbiprofen 8.75 mg lozenges for streptococcal and non-streptococcal sore throat: pooled analysis of two randomised, placebo-controlled studies. Abstract presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27 - 30 April 2013, Berlin.
  • Shephard A, Smith G, Aspley S, Schachtel B. Symptomatic relief in streptococcal and non-streptococcal sore throat patients: pooled analysis of two randomised, placebo-controlled studies. Abstract presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27-30 April 2013, Berlin.
  • Schachtel B, Aspley S, Berry P, Shephard A, Sanner K, Shea T, Smith G, Schachtel E. Chief Complaint: the therapeutogenic stimulus as the primary, individualized endpoint in clinical trials. Journal of Pain 2012;13(4)Supplement:S6.
  • Shephard A, Smith G, Aspley S, Schachtel BP. Randomised, double-blind, placebo-controlled studies on flurbiprofen 8.75 mg lozenges in patients with/without group A or C streptococcal throat infection, with an assessment of clinicians' prediction of 'strep throat'. Int J Clin Pract. 2015 Jan;69(1):59-71. doi: 10.1111/ijcp.12536. Epub 2014 Oct 9. PubMed 25296661 ↗
  • Schachtel B, Aspley S, Shephard A, Shea T, Smith G, Schachtel E. Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study. Trials. 2014 Jul 3;15:263. doi: 10.1186/1745-6215-15-263. PubMed 24988909 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2010
First posted
Jan 14, 2010
Start
Nov 2009
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Sep 21, 2017
Last update
Sep 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01048866
Responsible party
Sponsor
First posted
Jan 14, 2010
Start date
Nov 2009
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Sep 21, 2017
Last update
Sep 21, 2017

Study contacts

Timothy J Shea, BS
study director · Reckitt Benckiser Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flurbiprofen

Start the discussion